Recipharm Appoints new General Manager for Recipharm Italia SpA
Recipharm has appointed Giorgio Bruno has been appointed General Manager of Recipharm Italia SpA. In this role, he will serve as CEO for all of Recipharm’s Italian operating companies which employ some 257 people at three sites and have revenues of €57 million.
Dr Bruno has long established senior management experience from within the pharmaceutical industry, especially in the area of manufacturing. He has worked in both Italian and multinational pharmaceutical companies covering a wide range of disciplines. In particular he has had responsibility for quality and manufacturing at such companies including Parke Davis, AstraZeneca and Corden Pharma. Dr Bruno also has strong industry knowledge and has held a number of positions within Italian based industry associations. He holds a PhD.in Pharmaceutical Chemistry and Technology from the University of Milan.
Commenting on the appointment, Thomas Eldered, CEO of Recipharm remarked: “I am very pleased to welcome Dr Bruno to the Recipharm team. We are very fortunate to have been able to attract such a competent and highly experienced manager to this important position and I look forward to him bringing his expertise to bear across our Italian operations for which he is now responsible.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance